Acid α-glucosidase (AAG)
Acid α-glucosidase (AAG), also known as acid maltase or α-1,4-glucosidase, is an enzyme that hydrolyzes α-glucosidic bonds at the non-reducing ends of oligosaccharides, disaccharides, and glycogen, releasing free glucose.
Acid α-glucosidase (AAG), also known as acid maltase or α-1,4-glucosidase, is an enzyme that hydrolyzes α-glucosidic bonds at the non-reducing ends of oligosaccharides, disaccharides, and glycogen, releasing free glucose. Two distinct enzymes are commonly referred to under the α-glucosidase name: the lysosomal acid form, which degrades glycogen at acidic pH inside the lysosome, and the neutral-pH intestinal brush-border forms (maltase-glucoamylase and sucrase-isomaltase) that complete the terminal digestion of dietary starch after it has been broken down by salivary and pancreatic amylases such as AMY1C. Inherited deficiency of the lysosomal enzyme causes Pompe disease, a glycogen storage disorder treated by enzyme replacement therapy.
Pharmacologically, α-glucosidase is best known as a target for glycemic control. Because the intestinal enzyme governs the final step converting oligosaccharides to absorbable glucose, inhibiting it slows carbohydrate absorption and blunts postprandial glucose excursions — the mechanism of acarbose, the reference inhibitor used in type 2 diabetes mellitus and the standard positive control in inhibition assays. This makes the enzyme a common screening target in natural-product and food-science research, where plant phenolics and flavonoids (luteolin, rutin, chlorogenic acid, ferulic acid, gallic acid, caffeic acid, rosmarinic acid, resveratrol), soluble dietary fibers, and food-derived peptides are evaluated for inhibitory potency, typically alongside antioxidant assays measuring reactive oxygen species scavenging. Such studies often pair α-glucosidase inhibition with related endpoints relevant to metabolic and neurodegenerative disease, including insulin resistance, oxidative stress, and inhibition of acetylcholinesterase, butyrylcholinesterase, or tyrosinase, and commonly use molecular docking and molecular dynamics simulation to characterize how candidate inhibitors engage the enzyme's active site.
Where the papers sit
17 papers from the last 6 months study Acid α-glucosidase (AAG) directly · updated from PubMed 10 Oct 2026
Study type 0 clinical trials · 1 human data · 16 preclinical
Themes 3 themes · 1 new direction
-
Synthetic Enzyme Inhibitors
Synthetic hybrids are being optimized as dual α-amylase and α-glucosidase inhibitors, with acarbose providing a recurring benchmark. Molecular docking, structure-based modelling and enzyme kinetics connect chemical substitutions with inhibitory potency, while selected candidates advance to in vivo testing. Antioxidant effects and applications such as diabetic wound healing and diabetic colitis broaden the therapeutic rationale beyond glucose control. Translation remains early, with selectivity, pharmacokinetics and durable in vivo efficacy unresolved.
8 papers · 47.1%
-
Plant Phenolics and Glycemic Control
Plant phenolic extracts are being linked to postprandial glucose control through combined α-glucosidase and α-amylase inhibition, antioxidant activity and chemical profiling. Extraction method, tissue source and metabolite composition recur as explanations for differences in bioactivity across leaves, seeds, oils and whole plants. Several studies add antimicrobial or cholinesterase assays, but glucose-related enzyme inhibition remains the shared focus. Evidence is still predominantly in vitro, with limited in vivo validation and no established clinical direction.
6 papers · 35.3%
-
Nanomaterials for Diabetes
Nanoparticle platforms are being used both to deliver antioxidant or antidiabetic activity and to improve α-glucosidase assay performance. Silver and zinc oxide formulations are characterized by microscopy, spectroscopy, pH tolerance and related physicochemical measures, then assessed for antioxidant, anti-inflammatory, neuroprotective or glucose-lowering effects. ZIF-90 immobilization shifts the emphasis toward biomimetic screening of inhibitors from traditional medicines. The work remains mainly in vitro and preclinical, with efficacy, safety and biological translation still open.
3 papers · 17.6%
α-Glucosidase is repurposed as a stabilized, reusable screening platform rather than only an antidiabetic drug target
The double-shelled ZIF-90-immobilized α-glucosidase system developed for screening inhibitors from traditional Chinese medicines 42303022Jun departs from the set’s usual use of α-glucosidase as a therapeutic target whose activity is blocked by candidate compounds. Instead, the enzyme was biomimetically encapsulated in ZIF-90 to create a screening assay with improved pH and temperature tolerance, storage stability, and reusability, while retaining substrate affinity and increasing apparent maximum velocity. This changes α-glucosidase’s role from the object of inhibitor discovery to a durable analytical component that enables inhibitor screening.
Papers
The 17 papers from the last 6 months that study Acid α-glucosidase (AAG) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Synthetic Enzyme Inhibitors (8)
- Bioassay-guided isolation of antioxidant, antibacterial, and antidiabetic compounds from Aleuritopteris bicolor of Nepal: In vitro/in silico study. PloS one · 30 Jul 2026 PMID 42531324
- Biological evaluation and molecular docking of previously reported pyrazolo-thiazole derivatives as dual α-amylase and α-glucosidase inhibitors. Future medicinal chemistry · 23 Jun 2026 PMID 42333400
- Bioactive biphenyl derivatives from Garcinia nujiangensis and structural revision. Fitoterapia · 15 Jun 2026 PMID 42297079
- Enzyme kinetics-guided evaluation of thiazine hybrids targeting α-amylase and α-glucosidase with in vivo validation. Chemico-biological interactions · 12 May 2026 PMID 42119837
- Zwitterionic Lipid Nanotherapeutics from Mulberry for Oral Treatment of Diabetic Colitis. ACS nano · 11 May 2026 PMID 42112609
- In Vitro Evaluation of Novel Synthetic Benzimidazolium-Chalcone Hybrids: Antioxidant and Regenerative Effects in Diabetic Wound Healing. Applied biochemistry and biotechnology · 8 May 2026 PMID 42101574
- Structure-based design and molecular modelling of n-propylcarbazole-1,3-thiazole hybrids as potent α-glucosidase inhibitors: Kinetic, in vitro, and in vivo evaluation. Journal of molecular graphics & modelling · 25 Apr 2026 PMID 42033845
- Chromenone coupled to spiro[indene-2,3'-pyrrolizine]-1,3-diones as a novel class of α-glucosidase inhibitor. Bioorganic chemistry · 18 Apr 2026 PMID 42000452
Plant Phenolics and Glycemic Control (6)
- Unlocking the Role of Chia (Salvia hispanica L.) Seed Phenolic Metabolites in Postprandial Glucose Modulation: in vitro, in vivo, and Antioxidant Evidence Supported by Molecular Docking. Plant foods for human nutrition (Dordrecht, Netherlands) · 18 Jun 2026 PMID 42313210
- Antioxidant, antibacterial, in vitro, and in silico α-glucosidase inhibition activities and chemical profiling of Usnea cornuta Korb. PloS one · 12 Jun 2026 PMID 42284305
- Ultrasound-Assisted Extraction of Free and Bound Phenolics from Hawthorn (Crataegus azarolus) Leaves and their Antioxidant and Antidiabetic Activities. Plant foods for human nutrition (Dordrecht, Netherlands) · 15 May 2026 PMID 42141147
- In-vitro studies of phytochemical, Antioxidant, Antibacterial and Enzymatic inhibition of Oxalis corniculata whole plant from South Waziristan Tribal District Pakistan. PloS one · 14 May 2026 PMID 42133613
- Comparative metabolic profiling, enzyme inhibitory activities, and in-silico analysis of the hexane extract and the hydrodistilled oil of Boswellia serrata. PloS one · 8 May 2026 PMID 42102034
- Organ-Specific Phytochemical Composition and Bioactivity Profiling of Chaerophyllum aksekiense: A Multiassay Antioxidant, Enzyme Inhibition, and Correlation-Based Evaluation. ChemistryOpen · 29 Apr 2026 PMID 42051056
Nanomaterials for Diabetes (3)
- Biomimetic immobilization of α-glucosidase in double-shelled ZIF-90 for inhibitor screening from traditional Chinese medicines. International journal of biological macromolecules · 16 Jun 2026 PMID 42303022
- Fungal-mediated synthesis of silver nanoparticles using Porostereum spadiceum and their antioxidant, anti-inflammatory, and antidiabetic activities. The international journal of biochemistry & cell biology · 7 May 2026 PMID 42097278
- Formulation and characterization of ascorbic acid-based zinc oxide nanoparticles for assessing antidiabetic and neuroprotective effects in STZ-induced diabetic rats. Artificial cells, nanomedicine, and biotechnology · 28 Apr 2026 PMID 42047278
By study type
Human data, design not indexed (1)
- Bioactive biphenyl derivatives from Garcinia nujiangensis and structural revision. Fitoterapia · 15 Jun 2026 PMID 42297079
Preclinical: animal, cell and lab studies (16)
- Bioassay-guided isolation of antioxidant, antibacterial, and antidiabetic compounds from Aleuritopteris bicolor of Nepal: In vitro/in silico study. PloS one · 30 Jul 2026 PMID 42531324
- Biological evaluation and molecular docking of previously reported pyrazolo-thiazole derivatives as dual α-amylase and α-glucosidase inhibitors. Future medicinal chemistry · 23 Jun 2026 PMID 42333400
- Unlocking the Role of Chia (Salvia hispanica L.) Seed Phenolic Metabolites in Postprandial Glucose Modulation: in vitro, in vivo, and Antioxidant Evidence Supported by Molecular Docking. Plant foods for human nutrition (Dordrecht, Netherlands) · 18 Jun 2026 PMID 42313210
- Biomimetic immobilization of α-glucosidase in double-shelled ZIF-90 for inhibitor screening from traditional Chinese medicines. International journal of biological macromolecules · 16 Jun 2026 PMID 42303022
- Antioxidant, antibacterial, in vitro, and in silico α-glucosidase inhibition activities and chemical profiling of Usnea cornuta Korb. PloS one · 12 Jun 2026 PMID 42284305
- Ultrasound-Assisted Extraction of Free and Bound Phenolics from Hawthorn (Crataegus azarolus) Leaves and their Antioxidant and Antidiabetic Activities. Plant foods for human nutrition (Dordrecht, Netherlands) · 15 May 2026 PMID 42141147
- In-vitro studies of phytochemical, Antioxidant, Antibacterial and Enzymatic inhibition of Oxalis corniculata whole plant from South Waziristan Tribal District Pakistan. PloS one · 14 May 2026 PMID 42133613
- Enzyme kinetics-guided evaluation of thiazine hybrids targeting α-amylase and α-glucosidase with in vivo validation. Chemico-biological interactions · 12 May 2026 PMID 42119837
- Zwitterionic Lipid Nanotherapeutics from Mulberry for Oral Treatment of Diabetic Colitis. ACS nano · 11 May 2026 PMID 42112609
- Comparative metabolic profiling, enzyme inhibitory activities, and in-silico analysis of the hexane extract and the hydrodistilled oil of Boswellia serrata. PloS one · 8 May 2026 PMID 42102034
- In Vitro Evaluation of Novel Synthetic Benzimidazolium-Chalcone Hybrids: Antioxidant and Regenerative Effects in Diabetic Wound Healing. Applied biochemistry and biotechnology · 8 May 2026 PMID 42101574
- Fungal-mediated synthesis of silver nanoparticles using Porostereum spadiceum and their antioxidant, anti-inflammatory, and antidiabetic activities. The international journal of biochemistry & cell biology · 7 May 2026 PMID 42097278
- Organ-Specific Phytochemical Composition and Bioactivity Profiling of Chaerophyllum aksekiense: A Multiassay Antioxidant, Enzyme Inhibition, and Correlation-Based Evaluation. ChemistryOpen · 29 Apr 2026 PMID 42051056
- Formulation and characterization of ascorbic acid-based zinc oxide nanoparticles for assessing antidiabetic and neuroprotective effects in STZ-induced diabetic rats. Artificial cells, nanomedicine, and biotechnology · 28 Apr 2026 PMID 42047278
- Structure-based design and molecular modelling of n-propylcarbazole-1,3-thiazole hybrids as potent α-glucosidase inhibitors: Kinetic, in vitro, and in vivo evaluation. Journal of molecular graphics & modelling · 25 Apr 2026 PMID 42033845
- Chromenone coupled to spiro[indene-2,3'-pyrrolizine]-1,3-diones as a novel class of α-glucosidase inhibitor. Bioorganic chemistry · 18 Apr 2026 PMID 42000452
Written from 17 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.